Washington Trust Advisors Inc. Purchases New Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Washington Trust Advisors Inc. purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the third quarter, Holdings Channel reports. The firm purchased 152 shares of the biopharmaceutical company’s stock, valued at approximately $42,000.

Several other institutional investors also recently bought and sold shares of the business. Capital Research Global Investors lifted its position in shares of Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after buying an additional 214,908 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after purchasing an additional 201,784 shares during the period. AQR Capital Management LLC raised its position in shares of Alnylam Pharmaceuticals by 92.5% during the 2nd quarter. AQR Capital Management LLC now owns 271,619 shares of the biopharmaceutical company’s stock worth $65,862,000 after purchasing an additional 130,482 shares during the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in Alnylam Pharmaceuticals in the 1st quarter valued at about $18,886,000. Finally, Deerfield Management Company L.P. Series C acquired a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth about $29,111,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company’s stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $277.43 on Friday. The firm has a market cap of $35.78 billion, a price-to-earnings ratio of -105.89 and a beta of 0.39. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock’s 50-day moving average price is $274.17 and its 200 day moving average price is $230.84. Alnylam Pharmaceuticals, Inc. has a 12-month low of $141.98 and a 12-month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. During the same period last year, the firm posted $1.15 earnings per share. The business’s revenue for the quarter was down 33.3% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. The Goldman Sachs Group upgraded Alnylam Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their target price for the company from $198.00 to $370.00 in a research report on Friday, August 16th. Bank of America upped their target price on shares of Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Chardan Capital restated a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Barclays increased their price objective on shares of Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Finally, TD Cowen raised their target price on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Six analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $294.50.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.